Docket No.: 3494-0104PUS1

IN THE SPECIFICATION

Please replace the paragraph beginning at line 27 of page 3 (paragraph [0009] of the

published document), with the following paragraph:

Surprisingly we have found that it was possible to prevent the effect of Mycoplasma

infection by dosing VET-HBM similarly as by dosing tiamutine tiamutin, the best known anti-

mycoplasm antibiotics. Because of the considerable incidence of Mycoplasma infection

everywhere in the world, this fact has a big economical importance. The economical loss caused

by the Mycoplasma infections can be reduced by means of the use of VET-HBM. It can be

especially preferred this time when the utilization of the antibiotics is tried to press back in the

veterinary practice and in the yield-enhancement.

Please replace the paragraph beginning at the first line of page 18 (paragraph [0097] of

the published document), with the following paragraph:

Group 4. was infected in identical manner as Group 2., then after location in a fourth

room the animals were fed with a nutriment containing 200 mg/kg tiamutine tiamutin

(Biochemie GmbH, Kundl, Austria) in the course of the experiment.

Please replace the paragraph beginning at line 28 of page 18 (paragraph [0108] of the

published document), with the following paragraph:

MSW/TJS/ta

2

In the Group 1. all the animals were negative while in the Group 2. all the animals

exhibited air-pocket- and peritoneum inflammation of different severity. In the treated Group 3.

and Group 4. pathological alterations developed significantly more scarcely and their severity

was considerably more moderate than in the animals of Group 2.. The results of the groups

treated with VET-HBM and tiamutine tiamutin, respectively, did not differ from each other.

Please replace the paragraph beginning at line 2 of page 19 (paragraph [0110] of the

published document), with the following paragraph:

In the Group 2. in consequence of the infection the number of lymphohystiocytic

bronchitis and lobular interstitial pneumoniae increased significantly as compared to the non-

infected Group 1.. At the same time the parameters in the Group 3. and Group 4. treated VET-

HBM and tiamutine tiamutin, respectively, remained on the same level as in the Group 1., with

the exception of the lobular interstitial pneumoniae the number of which was significantly higher

in the Group 3., than in the control group. The Group 3. and Group 4. did not differ from each

other statistically as far as the alterations examined concerned.

Please replace the paragraph beginning at the first line of page 20 (paragraph [0116] of

the published document), with the following paragraph:

At the end of the experiment it was not possible to recultivate the strains employed to the

infection from the Group 1., while from the Group 2. it was possible to recultivate them in 64

MSW/TJS/ta

3

Docket No.: 3494-0104PUS1

instances first of all from the trachea, lung and air-pockets. On the other hand the re-isolation

was successful significantly more scarcely from the Group 3. and Group 4. (by 10 and 3

occasions, respectively), and only from some lungs and tracheae but not from other inner organs.

Substantial difference could not be observed between the groups treated VET-HBM and

4

tiamutine tiamutin, respectively.

MSW/TJS/ta